Statins cut heart attacks in healthy older adults but bring more muscle and diabetes trouble

For decades, doctors have debated whether it makes sense to put an otherwise healthy person in their seventies or eighties on a cholesterol-lowering drug they have never needed before, given how little direct trial evidence existed for that specific age group. A large randomized trial presented this year finally supplies some of that missing evidence, and the answer is more complicated than a simple yes or no. The drug cut the rate of major cardiovascular events by roughly a third, a substantial benefit by any standard, but it also came with a real increase in side effects tied to muscles, the liver, and blood sugar control.

The trial enrolled thousands of older adults who had never been diagnosed with heart disease, diabetes, or dementia, then tracked them for nearly six years.

Inside the STAREE Trial’s Design

The study, known as STAREE, randomly assigned nearly 10,000 adults over age 70 to receive either 40 milligrams of atorvastatin daily or an identical-looking placebo, none of whom had a prior history of cardiovascular disease, diabetes, or dementia at enrollment. That design matters because most of the statin evidence doctors have relied on for years came from trials that either excluded very old patients or included only a small number of them, leaving a gap in the evidence for a drug that is nonetheless routinely prescribed to people well into their eighties. Results were presented at the European Society of Cardiology’s 2026 congress, one of the field’s largest annual meetings.

A Roughly 30% Cut in Major Cardiovascular Events

Patients taking atorvastatin saw a 30% relative reduction in major cardiovascular events compared with the placebo group over a median follow-up of nearly six years, according to trial coverage from Medscape. The benefit was driven mainly by a reduction in nonfatal events, such as heart attacks and strokes that did not result in death, rather than a large drop in cardiovascular deaths specifically. Researchers described the finding as the first large-scale evidence that a statin, used purely for primary prevention in patients who have never had a cardiovascular event, produces a measurable benefit in people who are already well into their seventies and eighties.

More Muscle, Liver, and Diabetes-Related Side Effects

The benefit did not come free of tradeoffs. Musculoskeletal problems, liver-related issues, and new diabetes diagnoses all occurred more frequently in the atorvastatin group than in the placebo group, a pattern consistent with side effects statins are already known to cause in younger patients, but one that had not been well documented specifically in a trial population this old. Despite that increase in specific side effects, the overall rate of serious adverse events was nearly identical between the two groups, at 2.7% in each, according to trial summaries presented at the congress. That distinction, between an uptick in specific, generally manageable side effects and no overall increase in serious harm, is likely to shape how cautiously doctors weigh the tradeoff for individual patients.

No Extra Years of Disability-Free Living

One of the trial’s original goals was to see whether statins could extend disability-free survival in older adults, not just prevent heart attacks and strokes. On that measure, the drug came up short: rates of death, dementia, and persistent physical disability were similar between the atorvastatin and placebo groups, with 637 such outcomes in the statin group compared with 676 in the placebo group, a difference researchers did not describe as statistically meaningful. In other words, taking the drug reduced the odds of a cardiovascular event, but it did not translate into more years of independent, disability-free living overall, an outcome that may matter as much to older patients and their families as the cardiovascular numbers themselves.

Who Ran the Trial, and Why It Was Needed

STAREE was led by Professor Sophia Zoungas of Monash University’s School of Public Health and Preventive Medicine in Melbourne, with funding from Australia’s National Health and Medical Research Council and the Heart Foundation of Australia, and its full results were published simultaneously in the New England Journal of Medicine alongside the ESC presentation. “An estimated 21,000 older Australians suffer from major cardiovascular events, like heart attack and stroke, each year,” Zoungas said in presenting the findings, framing the trial as an answer to a question that had gone unanswered for decades: whether statins actually extend healthy life in patients who start taking them only once they are already elderly, rather than in the middle-aged patients most existing statin trials had enrolled.

The trial ultimately randomized 9,971 participants in total, split evenly between atorvastatin and placebo, with a mean age of 74.7 and women making up 52% of participants. Major cardiovascular events occurred in 6.0% of the atorvastatin group compared with 8.3% of the placebo group, a difference researchers calculated had less than a one-in-a-thousand probability of being due to chance. Zoungas said she hoped the results would prompt updated clinical guidelines specific to older patients, a group that has historically been treated more by extrapolation from younger trial populations than by direct evidence of its own.

What the Findings Mean for Prescribing Decisions

Cardiologists reviewing the trial, including commentary summarized by the American College of Cardiology, have generally framed the results as supportive of starting statins in healthy older adults rather than assuming age alone is a reason to avoid them, while also cautioning that the side-effect data should factor into individualized conversations between doctors and patients. For a patient in their mid-seventies with no history of heart disease, the trial suggests a real, measurable benefit is available from starting a statin, but also that the decision should account for personal risk factors like existing muscle or liver conditions and family history of diabetes, rather than being treated as a one-size-fits-all recommendation for anyone past a certain age.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview